Is Raymed Labs Ltd debt-free?

Yes, Raymed Labs Ltd is debt-free with a debt-to-equity ratio of -0.92.

Home

Raymed Labs Ltd

Raymed Labs Ltd Financials

Raymed Labs Ltd Financial Statement

Raymed Labs Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars	Mar 2025	Dec 2024	Sep 2024
Revenue	0.52	0.01	TBA
Operating Expense	0.33	0.26	0.02
Net Profit	0.07	-0.25	-0.02
Net Profit Margin	13.46	-2,500	TBA
Earning Per Share	0.16	-0.58	-0.04
EBIDTA	0.18	-0.25	-0.02
Effective Tax Rate	TBA	TBA	TBA

Particulars	Mar 2025
Revenue	0.52
Operating Expense	0.33
Net Profit	0.07
Net Profit Margin	13.46
Earning Per Share	0.16
EBIDTA	0.18
Effective Tax Rate	TBA

Raymed Labs Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Total Revenue Annual	TBA	TBA	TBA
Operating Expenses Annual	0.10	0.19	0.08
Operating Profit Annual	-0.10	-0.17	-0.08
Interest Annual	TBA	0.00	TBA
Depreciation	0.00	0.01	0.01
Net Profit Annual	-0.10	-0.17	-0.08
Tax Annual	TBA	TBA	TBA

Particulars	Mar 2024
Total Revenue Annual	TBA
Operating Expenses Annual	0.10
Operating Profit Annual	-0.10
Interest Annual	TBA
Depreciation	0.00
Net Profit Annual	-0.10
Tax Annual	TBA

Raymed Labs Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Cash Flow at the Beginning	TBA	TBA	TBA
Cash Flow from Operations	-0.06	-0.16	-2.21
Cash Flow from Investing	0.06	0.16	2.21
Cash Flow from Financing	TBA	TBA	TBA
Cash Flow at the End	TBA	TBA	TBA

Particulars	Mar 2024
Cash Flow at the Beginning	TBA
Cash Flow from Operations	-0.06
Cash Flow from Investing	0.06
Cash Flow from Financing	TBA
Cash Flow at the End	TBA

Raymed Labs Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
PBDIT Margin (%)	TBA	TBA	TBA
PBIT Margin (%)	TBA	TBA	TBA
PBT Margin (%)	TBA	TBA	TBA
Net PROFIT Margin (%)	TBA	TBA	TBA
Return On Networth / Equity (%)	TBA	TBA	TBA
Return On Networth /Employed (%)	TBA	TBA	TBA
Return On Assets (%)	TBA	TBA	TBA
Total Debt / Equity (X)	TBA	TBA	TBA
Asset Turnover Ratio (%)	TBA	TBA	TBA

Particulars	Mar 2024
PBDIT Margin (%)	TBA
PBIT Margin (%)	TBA
PBT Margin (%)	TBA
Net PROFIT Margin (%)	TBA
Return On Networth / Equity (%)	TBA
Return On Networth /Employed (%)	TBA
Return On Assets (%)	TBA
Total Debt / Equity (X)	TBA
Asset Turnover Ratio (%)	TBA

Raymed Labs Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Fixed Assets Annual	0.15	0.15	0.16
Total Current Assets Annual	0.01	0.01	0.09
Non Current Assets Annual	0.15	0.15	0.16
Total Shareholders Funds Annual	-2.41	-2.31	-2.13
Total Assets Annual	0.15	0.16	0.25

Particulars	Mar 2024
Fixed Assets Annual	0.15
Total Current Assets Annual	0.01
Non Current Assets Annual	0.15
Total Shareholders Funds Annual	-2.41
Total Assets Annual	0.15

Raymed Labs Ltd Earning Calls

No Data Availabe

Dividend Pages

PE Ratio

FAQS on Raymed Labs Ltd Financials

As of Jun 16, 2025, Raymed Labs Ltd has a market capitalization of 1.35 Cr. Value Research classifies it as a Micro-Cap company.

Yes, Raymed Labs Ltd is with a debt-to-equity ratio of -0.92.

In FY 2024 , Raymed Labs Ltd recorded a total revenue of approximately 0 Cr marking a significant milestone in the company's financial performance.

Raymed Labs Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.2% and NaN% annually, respectively..

Raymed Labs Ltd's current PE ratio is -7.50.

Raymed Labs Ltd's ROCE averaged -217.4% from the FY ending March 2023 to 2025, with a median of -262.5%. It peaked at 30.3% in March 2025, reflecting strong capital efficiency over the period..

Raymed Labs Ltd's latest EBIT is Rs. -0.07 Cr, surpassing the average EBIT of Rs. -0.11 Cr over the 5 years..